Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
NCT01540929 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5001
Last updated 2024-03-18
Summary
This is a retrospective study of the Department of Defense (DoD) Smallpox Screening Form 600s (SF600s) generated during screening of service members for possible immunization with the ACAM2000® smallpox vaccine.
Primary Objective:
* To evaluate the accuracy of the DoD smallpox vaccination screening process in military personnel.
Secondary Objective:
* To describe the number of subjects who are excluded from vaccination, stratified by the pre-defined categories for exclusion (separately for the Screened and Evaluable Populations).
Conditions
Sponsors & Collaborators
-
Emergent BioSolutions
lead INDUSTRY
Principal Investigators
-
Medical Director · Emergent BioSolutions
Eligibility
- Min Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-09-30
- Primary Completion
- 2012-09-30
- Completion
- 2012-09-30
Countries
- United States
Study Locations
More Related Trials
-
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
NCT01913353 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
NCT00053508 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine
NCT00466245 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults
NCT00026611 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects
NCT00857493 ·Status: COMPLETED ·Phase: PHASE2
-
ACAM 3000 MVA at Harvard Medical School
NCT00133575 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
NCT05762523 ·Status: COMPLETED ·Phase: PHASE1
-
Human Immune Responses Smallpox
NCT00068198 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.
NCT00189956 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®
NCT01827371 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
NCT00050505 ·Status: COMPLETED ·Phase: PHASE2
-
High Dose IMVAMUNE® in Vaccinia-Naive Individuals
NCT00879762 ·Status: COMPLETED ·Phase: PHASE2
-
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
NCT05846243 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Dryvax Dilution-Prev Vacc Adults
NCT00032708 ·Status: COMPLETED ·Phase: PHASE2
-
Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT
NCT05745987 ·Status: RECRUITING ·Phase: PHASE4
-
SIGA-246 to Treat Smallpox
NCT00303225 ·Status: WITHDRAWN ·Phase: PHASE1
-
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
NCT03699124 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
NCT01979406 ·Status: COMPLETED ·Phase: PHASE1
-
A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)
NCT02180295 ·Status: WITHDRAWN ·Phase: PHASE3
-
Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial
NCT06926062 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults
NCT00079820 ·Status: COMPLETED ·Phase: PHASE1
-
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
NCT00914732 ·Status: COMPLETED ·Phase: PHASE2
-
VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
NCT01374984 ·Status: ENROLLING_BY_INVITATION
-
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees
NCT00686582 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
NCT06771479 ·Status: RECRUITING ·Phase: PHASE1